Experience with intensive chemotherapy for relapsed/refractory multiple myeloma (RRMM) using VDT PACE regimen and its modifications (VDT PACE-like regimens: VPLRs) outside TOTAL THER-APY trials is limited. We analyzed the outcomes of 141 patients with RRMM who received VPLRs at our center between 2006 and 2017 in an intent-to-treat analysis. Median age was 59.7 years and 66.7% of patients were male. A median of 2.2 years (range 0.02-11.4) separated diagnosis of myeloma and inititation of VPLR. High-risk cytogenetics were present in 52.4% patients. Patients received a median of 4 (range 1-14) prior therapies, including stem cell transplant (SCT) in 66.7% patients. Ninety-five (67.4%) patients received VDT PACE, 20 (14.2%) patients received VD PACE and 26 (18.4%) patients received other VPLRs. Patients received a median of 1 cycle (range 1-9) of VPLR. We observed minimal response in 68.4%, partial response (PR) in 54.4% and very good PR in 10.3% patients. Median progression-free survival was 3.1 months (95% CI, 1.9-3.9) and median overall survival (OS) was 8.1 months (CI, 6.2-9.9). One-hundred and sixteen (82.3%) patients received some therapy after VPLR; 71 (61.2%) received systemic chemotherapy, while 45 However, a cure for MM is still elusive. Patients who were exposed to at least 3 prior lines of therapy, were refractory to a PI and an IMiD, and were exposed to an alkylating agent, had an OS of only 13 months and progression-free survival (PFS) of 5 months in a recent multicenter study. 
which showed that addition of thalidomide to intensive infusional chemotherapy with conventional agents and tandem SCT improves response rates. 5, 6 DT PACE used cisplatin and etoposide to which most patients with MM are not exposed. The 24-hour infusion of PACE was aimed at providing continuously high plasma drug levels to target slowly dividing, resistant plasma cell clones, and to reduce cardiotoxicity related to doxorubicin. 7, 8 DT PACE was modified with addition of bortezomib (VDT PACE) in the TOTAL THERAPY-3 protocol, and comparative studies have
shown sustained remissions and improvement in OS, presumably related to bortezomib. 9, 10 Treatment with VDT PACE can be difficult to tolerate and is often associated with high incidence of therapy related adverse events including severe cytopenias, neuropathy, and thromboembolic events. 9, 11 Our group favors the use of VDT PACE as a bridge to SCT or further chemotherapy in patients with MM refractory to multiple first and second generation novel agents or with MM and extensive extramedullary plasmacytomas. 12 Experience with VDT PACE and its modifications, together designated VDT PACE-like regimens (VPLRs) outside the TOTAL THERAPY studies is limited. 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] We aimed to review the outcomes of patients treated with VPLRs for RRMM at our center.
| M E TH ODS

| Patients
We searched our electronic database of patients with MM to identify those who received their first VPLR between 2006 and March 2017 at Mayo Clinic, Rochester, MN. For inclusion in the study, patients had to receive VDT-PACE regimen or any of its modifications. We included all patients who started the protocol in the final analysis in an intentionto-treat model. We excluded patients with plasma cell leukemia, and those who received VPLR as front-line therapy for MM. We collected data for all patients regarding the time of diagnosis, therapy including SCT prior to initiation of VPLR, characteristics at initiation of VPLR, best response to VPLR, subsequent therapy including SCT, disease progression, and survival status at last follow-up, by reviewing their electronic medical records. The data cut-off date was July 15, 2017. The study was approved by the Mayo Clinic institutional Review Board, and was conducted in accordance with the Declaration of Helsinki and the Health Insurance Portability and Accountability Act guidelines of 1996.
All patients included in the analysis had a diagnosis of MM established prior to starting therapy as per standard diagnostic criteria. 22, 23 Relapsed and refractory MM were defined according to current guidelines. 24 We counted the lines of therapy prior to initiation of VPLR as per consensus recommendations. 25 International staging system (ISS) stage and the revised international staging system (R-ISS) stage were calculated when the required parameters were available before the initiation of VPLR. 26, 27 Interphase fluorescent in situ hybridization (iFISH) testing was done on bone marrow plasma cells as previously described, and the results of iFISH done before and closest to initiation of VPLR were used to risk stratify patients into high-risk [presence of any of del (17p), t(4; 14), t(14; 16), and t(14; 20)] or standard-risk (absence of all the above) cytogenetic categories. [28] [29] [30] The VPLRs used at our institution were based on the regimens described by Lee et al. 4 (DT PACE) and Barlogie et al. 9 (VDT PACE). 
| Response and outcomes
The primary end point was the response to VPLR. Secondary end points included OS, PFS, and adverse events to therapy. Response to therapy was assessed after C1 of VPLR and the best response obtained during all cycles of VPLR was also estimated. The responses to VPLR and disease progression were defined according to the recently updated International Myeloma working Group guidelines. 31 In patients who proceeded to another therapy including SCT immediately after attaining the best response, the response assessments were based on a single set of laboratory tests, and not confirmed. Overall response rate (ORR) was defined as the proportion of patients attaining a partial response (PR) or better, and clinical benefit rate (CBR) denoted the proportion of patients attaining minimal response (MR) or better. OS was defined as the duration from initiation of VPLR to death, patients being censored if they were known to be alive at the date of last follow-up.
PFS was defined as duration of survival free of progression while on VPLR, and was calculated as time from initiation of VPLR to disease progression or death, which ever was earlier. Patients were censored in PFS analysis if they started another therapy including SCT before progression. To ensure comparability between patients, we documented adverse events only during C1 of VPLR (upto 6 weeks from initiation of C1 of VPLR, or upto initiation of C2 of VPLR, or upto SCT, whichever was earlier). We documented the occurrence vs. non-occurrence of febrile neutropenia and renal failure attributed to therapy (increase in serum creatinine by 0.3 mg/dL above or 1.5 times the baseline serum creatinine), and used re-hospitalization during C1 as a surrogate marker for serious adverse events. We also assessed the time to recovery of ANC and platelet count, and requirement of blood product transfusion support during C1. Recovery of ANC was defined as ANC 0.5 
| Statistical analysis
Continuous variables were summarized as medians, and categorical variables were summarized as proportions. Fisher's exact test and McNemar's test were used to compare categorical variables as appropriate.
The time-to-event analyses were performed using the Kaplan Meier method and compared between groups using log-rank test. Univariate and multivariate Cox proportional hazards model were used to predict the impact of baseline characteristics on OS. A P-value < .05 was considered significant for all statistical tests. We used JMP Pro 12.0 (SAS Institute Inc., Cary, NC) for statistical analysis.
| R E SU LTS
We identified 141 patients who received VPLRs for RRMM. The characteristics of these patients at initiation of VPLR are shown in Table 1 .
About two-third of all patients were male, and a median of 2.2 years had elapsed from diagnosis of MM to initiation of VPLR. Patients were heavily pre-treated as shown by a median of 4 prior lines of therapy.
Ninety-six percent of patients were refractory to their last line of therapy. Among all patients, 66.7% had undergone prior ASCT, while none had undergone an allogeneic SCT. Fifteen (10.6%) patients had undergone 2 ASCTs. Fifty-two percent of patients had high-risk cytogenetics on iFISH, and 36% patients had extramedullary disease. One-hundred and five (74.5%) patients were refractory to a PI and an IMiD, while 16 (7.8%) patients were refractory to doxorubicin. Seventy-eight (55.3%) patients were refractory to an alkylating agent. None of the patients were exposed to cisplatin or etoposide before.
| Treatment
Patients received a median of 1 cycle (range, 1-9) of VPLR. 
| Response to therapy
The response to VPLRs after C1 and the best response during the entire course of VPLRs in 136 evaluable patients are shown in Table 2 .
Response was not evaluated in 4 patients who died during C1 and in 1 patient who opted comfort care after C1. Among 45 patients who received 2 cycles of VPLR, the VGPR or better rate, ORR and CBR after C1 were 11.1% (n 5 5), 71.1% (n 5 32), and 77.8% (n 5 35)
respectively. During the entire course of VPLR, VGPR or better rate, ORR and CBR in these patients improved to 20% (n 5 9), 82.2%
(n 5 37), and 88.9% (n 5 40) respectively (P 
| Survival analyses
The median follow-up duration was 60.5 months (95% CI, 43.7-79.0) from starting VPLR. During follow-up, 116 patients died, and 29 patients (20.6%) died within 100 days from starting VPLR. The estimated median OS from initiation of VPLR was 8.1 months (95% CI, 6.2-9.9). The estimated median PFS was 3.1 months (95% CI, 1.9-3.9) (Figure 1 ). An estimated 31.6% and 17.5% patients were surviving at 12 months and 24 months respectively from initiation of VPLR. In a landmark analysis, among patients who were alive at D 1 30 from initiation of VPLR, those who attained at least a MR after C1 showed a trend towards improvement in OS [8.6 months (95% CI, 6.3-9.9) vs.
5.0 months (95% CI, 2.7-9.3); P 5 .149]. There was no difference in OS 
| Predictors of OS
| Adverse events and related morbidity
Patients were hospitalized for a median of 6 days (range, 4-42) during actual administration of drugs in C1. Seventy-seven (55.4%) patients had re-admission after administration of chemotherapy during C1 with a median of 1 (range, 1-3) re-admission. Data on re-hospitalization during C1 were not available for 2 patients. Median cumulative duration of hospital stay was 9 days (range, 4-42) during C1. Neutropenic fever and nephrotoxicity were seen during C1 in 51 (36.9%) and 20 (14.8%) patients respectively, among those with available data. OS was short in 
| D I SCUSSION
We describe the outcomes of a group of patients who received VPLRs at our center and had exhausted most available therapeutic agents.
After 1 or more cycles of VPLR, we observed a CBR of 68%, ORR of 54%, and VGPR or better as the best response in 10% patients. The median OS was 8.1 months. VPLRs afforded a PFS of 3.1 months. Complications during C1 of VPLR such as febrile neutropenia, and resultant re-hospitalizations (2 or more) were associated with reduced OS.
DT PACE was used as induction strategy in patients who had received at least 2 prior cycles of chemotherapy in the prospective trial reported by Lee et al. 4 About 63% of patients had RRMM, and most patients had been treated with VAD (vincristine, doxorubicin and dexamethasone) or melphalan-based regimens before DT PACE. None of the patients had undergone a SCT before. 4 In contrast, the TOTAL THERAPY-3 protocol which introduced VDT PACE, enrolled newly diagnosed patients with MM, and VDT PACE was used as induction and consolidation strategy in patients who underwent double SCT. 9 Apart from these clinical trials, there have been only a few retrospective studies which examined the use of VDT PACE or its modifications in patients with RRMM. 11, 13, 14, [16] [17] [18] [19] [20] [21] To put our results in context, the salient features of the important retrospective studies have been summarized in Supporting Information Appendix.
In our cohort, VPLRs were primarily used for cytoreduction prior to SCT or salvage chemotherapy. Most patients received only 1-2 cycles of VPLR. The ORR of 54% seen in our cohort is similar to the 50%-60%
ORR reported in most series. 13, 14, 16, [18] [19] [20] [21] Lee et al. 4 reported reduction in paraprotein by more than 50% in 86% patients and Muchtar et al.
11
reported a 75% ORR; the lower ORR in our cohort is probably related to the heavily pre-treated and refractory nature of the disease compared with the above 2 studies. 11 The proportion of patients who attained a VGPR was only 10% in our series compared to 35% in the series from Muchtar et al., 11 further illustrating the differences in the cohorts. Griffin et al. 21 in their comparative study of infusional therapies [VDT PACE, DCEP, and cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD)], showed ORR of 73% with VDT PACE and 52% with DCEP. In this study, only 41% and 54% of patients respectively in the VDT PACE and DCEP cohorts were refractory to lenalidomide and bortezomib, compared to 65% in our cohort. Seventy-four percent patients in our cohort were refractory to a PI and an IMiD. The VDT PACE cohort was less heavily pre-treated and only 46% patients had received a prior SCT. 21 These differences could explain the higher ORR seen in the VDT PACE group compared to our cohort.
The median OS from initiation of VPLR in our cohort was only 8.1 months confirming the poor outlook for these patients, as seen in most studies, except the SCT cohort reported by Beyer et al. 19 Patients who had at least a MR after VPLR showed a trend towards longer OS.
Higher proportion of these patients underwent SCT (40% vs. 23.9%).
Patients who had complications during C1 such as febrile neutropenia and had 2 re-admissions had shorter OS. Therapy with VPLRs resulted in a PFS of 3.1 months among our patients, which is similar to the PFS (3.7 months) observed by Park et al., 17 who reported the use of DCEP and employed a strategy similar to ours for calculation of PFS.
The disease control and PFS obtained can be used to perform SCT as a potential means to obtain durable remission in eligible patients. Previous studies have suggested that SCT after a VPLR may improve 16 noted that PS, prior ASCT, hemoglobin and platelet count predict OS in patients receiving DT PACE. The median time to recovery of ANC and platelet count were comparable to those reported by Gerrie et al., 16 but the requirement for packed red cell and pooled platelet transfusions were higher in our cohort, which can be partly explained by the lower bone marrow reserve in our patients (lower median hemoglobin and high bone marrow plasma cell percentage).
The major strength of our study is the large cohort of patients with RRMM treated at our center. Data on high-risk characteristics, and further treatment were available in most patients. Our major limitations include the retrospective study design with the attendant limitations in data retrieval and interpretation. A reliable assessment of PS was not available for majority of patients, and hence could not be used in the analysis. We did not use SCT as a time-dependent variable in the multivariate model to predict OS, because we aimed to identify the baseline factors which can be used as predictors.
In conclusion, 1-2 cycles of a VPLR can be used to reduce disease burden in patients with RRMM who have exhausted most other available therapies. In fit patients with aggressive disease, VPLRs can help in obtaining a window for SCT. Similarly, in transplant ineligible patients, VPLRs can be used to reduce disease burden while waiting enrollment in a clinical trial or before less intensive chemotherapy.
VPLRs provide a viable option in patients who are refractory to multiple commonly used agents, and have the potential to be modified with addition of newer PIs and IMiDs, and monoclonal antibodies. Cisplatin and etoposide are drugs to which most patients with RRMM are not exposed. The drug regimen should be individualized considering the prior drug exposure, general condition of the patient, and potential toxicity to maximize benefits and reduce ill effects.
